Wang, Feifei published the artcileAssociation between potentially inappropriate medication and adverse drug reactions in hospitalized elderly patients, HPLC of Formula: 72509-76-3, the main research area is potentially inappropriate medication adverse drug reaction hospitalized human; adverse drug reactions; hospitalized; inappropriate medicine.
The Beers, European Union (EU) and Screening Tool of Older Persons’ potentially inappropriate Prescription (STOPP) criteria were developed to improve the safe use of medicines in the elderly. However, the predictive validity of existing criteria to detect adverse drug reactions (ADRs) remains unexplored. The objective of the current study was to determine whether the 2019 Beers, 2015 STOPP or 2015 EU potentially inappropriate medicine (PIM) criteria were associated with ADRs. A retrospective, cross-sectional investigation was conducted among older persons (â?0 years of age) admitted to a tertiary hospital in China between Apr. 2019 and Dec. 2019. PIMs were identified as per the Beers, EU and STOPP criteria definitions. ADRs were retrospectively evaluated by two clin. pharmacists using the Naranjo algorithm. Multivariate logistic regression was used to evaluate the factors associated with ADRs in the hospitalized patients. The study participants included 560 hospitalized patients (mean age 72.05 8.15). The prevalence of patients receiving at least one PIM was 52.1%, 37.0% and 42.9% according to the Beers, EU and STOPP criteria, resp. Univariate anal. showed that ADRs were associated with PIMs listed in the Beers criteria (OR: 2.093, 95% CI: 1.028-4.263, 0.042), but not with the STOPP-listed (OR: 0.536, 95% CI: 0.255-1.123, 0.098) and EU-listed PIMs (OR: 0.258, 95% CI: 0.118-0.563, 0.001). In contrast to the STOPP and EU criteria on PIMs, the Beers criteria were significantly associated with avoidable ADRs in hospitalized older persons.
Journal of Clinical Pharmacy and Therapeutics published new progress about Algorithm. 72509-76-3 belongs to class pyridine-derivatives, name is 3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, and the molecular formula is C18H19Cl2NO4, HPLC of Formula: 72509-76-3.